WO 2006/116136

PCT7US2006/015172

DIHYDROBENZOFURAN DERIVATIVES AND USES THEREOF
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to United States Provisional Patent Application
serial number 60/674,060, filed April 22, 2005, the entirety of which is hereby incorporated
herein by reference.
FIELD OF THE INVENTION
[0002] The present invention relates to melatonin agonists or partial agonists, processes
for their preparation, and uses thereof.
BACKGROUND OF THE INVENTION
[0003] Melatonin, which is a widely used over-the-counter therapy for the treatment of
sleep disorders, is a natural hormone produced and secreted by the pineal gland. It acts at two
G-protein coupled receptors (MT1 and MT2), which are negatively coupled to adenylyl
cyclase and which play a role in the regulation of sleep and circadian rhythym by controlling
neuronal firing in the suprachiasmat'ic nucleus of the thalamus. Melatonin agonists and
partial agonists have the potential to improve sleep quality by resynchronizing the disrupted
rhythymicity of sleep/wake cycles.

[0005] The compounds of the present invention have potent affinity for melatonin MT1
and MT2 receptors and are thus useful for controlling sleep disorders and for the treatment of
[0004] In addition, melatonin agonists such as agomelatine have been shown to be active
in animal models predictive of clinical antidepressant efficacy, such as the Chronic Mild
Stress model [Neuropsychopharmacology 28(4), 694 (2003)] and the Forced Swim Test
[Journal of Psychiatry and Neuroscience, 29(2), 126 (2004)]. Agomelatine has recently been
reported to be active in clinical trials for the treatment of depression [L'Encephale 29(2), 165
(2003) and www.medicalnewstoday.com. April 5, 2005].

WO 2006/116136 PCT/US2006/015172
2
depression. In addition, the compounds of the present invention are capable of being
hydrolyzed in vivo (ie, acting as pro-drugs) to agents with potent agonist and partial agonist
effects at serotonin 5-HT2C receptors. 5-HT2C agonists represent a novel therapeutic approach
toward the treatment of schizophrenia. Several lines of evidence support a role for 5-HT2C
receptor agonism as a treatment for schizophrenia. Recent studies have demonstrated that 5-
HT2C agonists decrease levels of dopamine in the prefrontal cortex and nucleus accumbens
(Milan, M. J., et. al., Neuropharmacology 37: 953-955, 1998; Di Matteo, V., et. al.,
Neuropharmacology 38: 1195-1205,1999; Di Giovanni, G., et. al., Synapse 35: 53-61,2000),
brain regions that are thought to mediate critical antipsychotic effects of drugs like clozapine.
In contrast, 5-HT2C agonists do not decrease dopamine levels in the striatum, the brain region
most closely associated with extrapyramidal side effects. In addition, a recent study
demonstrates that 5-HT2C agonists decrease firing in the ventral tegmental area (VTA), but
not in substantia nigra Di Matteo and Di Giovanni, op. cit). The differential effects of 5-
HT2C agonists in the mesolimbic pathway relative to the nigrostriatal pathway suggests that
5-HT2C agonists will have limbic selectivity and will be less likely to produce extrapyramidal
side effects associated with typical antipsychotics.
[0006] Atypical antipsychotics bind with high affinity to 5-HT2C receptors and function
as 5-HT2C receptor antagonists or inverse agonists. Weight gain is a problematic side effect
associated with atypical antipsychotics such as clozapine and olanzapine and it has been
suggested that 5-HT2C antagonism is responsible for the increased weight gain. Conversely,
stimulation of the 5-HT2C receptor is known to result in decreased food intake and body
weight (Walsh et. al., Psychopharmacology 124: 57-73, 1996; Cowen, P. J., et. al., Human
Psychopharmacology 1_0: 385-391, 1995; Rosenzweig-Lipson, S., et. al., ASPET abstract,
2000). As a result, 5-HT2C agonists will be less likely to produce the body weight increases
associated with current atypical antipsychotics. Indeed, 5-HT2C agonists are of great interest
for the treatment of obesity, a medical disorder characterized by an excess of body fat or
adipose tissue and associated with such comorbidities as Type II diabetes, cardiovascular
disease, hypertension, hyperlipidemia, stroke, osteoarthritis, sleep apnea, gall bladder disease,
gout, some cancers, some infertility, and early mortality. Other therapeutic indications for 5-
HT2C agonists are obsessive compulsive disorder, depression, panic disorder, sleep disorders,
eating disorders and epilepsy.

WO 2006/116136 PCT/US2006/015172
3
SUMMARY OF THE INVENTION
[0007] The present invention relates to certain melatonin agonists or partial agonists and
uses thereof. The compounds of the present invention are useful, for example, to treat
depression and sleep disorders.
[0008] In certain embodiments, the invention provides a compound of formula I:

or pharmaceutically acceptable salts thereof, wherein:
m is 1 or 2;
n is 0 or 1;
y is O, 1,2, or 3;
each R1 is independently -CN, halogen, -R, or -OR;
each R is independently hydrogen, CM aliphatic, or fiuoro-substituted C1.4 aliphatic;
Ar is thienyl, furyl, pyridyl, or phenyl wherein Ar is optionally substituted with one or more
Rx groups;
each Rx is independently halogen, phenyl, -CN, -R, or -OR;
R2 is hydrogen or C1.4 aliphatic; and
X is -0-, -S-, -S(O)-, -SO2- or -CH2-.
[0009] In certain other embodiments, the invention relates to methods for treating a
patient suffering from a melatoninergic disorder comprising administering to the patient a
therapeutically effective amount of a compound of formula I, or a pharmaceutically
acceptable salt thereof.
[0010] In still other embodiments, the invention relates to compositions comprising a
compound of formula I or a pharmaceutically acceptable salt thereof, and one or more
pharmaceutically acceptable carriers, excipients, or diluents.
DETAILED DESCRIPTION OF THE INVENTION
1. Compounds and Definitions:
[0011] The present invention relates to compounds as described herein that are agonists
or partial agonists of melatonin.

WO 2006/116136 PCT/US2006/015172
4
[0012] The term "aliphatic" or "aliphatic group," as used herein, means a straight-chain
(i.e., uubranched) or branched, substituted or unsubstituted hydrocarbon chain that is
completely saturated or that contains one or more units of unsaturation, or a monocyclic
hydrocarbon that is completely saturated or that contains one or more units of unsaturation,
but which is not aromatic (also referred to herein as "carbocycle" "cycloaliphatic" or
"cycloalkyl"), that has a single point of attachment to the rest of the molecule. In certain
embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms, and in yet other
embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms. In some embodiments,
"cycloaliphatic" (or "carbocycle" or "cycloalkyl") refers to a monocyclic C3-C4 hydrocarbon
that is completely saturated or that contains one or more units of unsaturation and has a single
point of attachment to the rest of the molecule. Suitable aliphatic groups include, but are not
limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and
hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
[0013] The term "unsaturated," as used herein, means that a moiety has one or more units
of unsaturation.
[0014] The term "fluoro-substituted," as used herein, means that one or more hydrogen
atoms are replaced by fluorine atoms. In certain embodiments, the term fluoro-substituted
aliphatic refers to perfluoro-substituted aliphatic in which all hydrogen atoms are replaced by
fluorine atoms. Such groups include -CF3.
[0015] The term "lower alkyl," as used herein, refers to a hydrocarbon chain having up to
4 carbon atoms, preferably 1 to 3 carbon atoms, and more preferably 1 to 2 carbon atoms.
The term "alkyl" includes, but is not limited to, straight and branched chains such as methyl,
ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or t-butyl.
[0016] The term "alkoxy," as used herein, refers to the group -OR , wherein R is a lower
alkyl group.
[0017] The terms "halogen" or "halo," as used herein, refer to chlorine, bromine, fluorine
or iodine.
[0018] The term "alkenyl," as used herein refers to an aliphatic straight or branched
hydrocarbon chain having 2 to 4 carbon atoms that may contain 1 to 3 double bonds.
Examples of alkenyl groups include vinyl, prop-1-enyl, allyl, methallyl, but-1-enyl, but-2-
enyl, but-3-enyl, or 3,3-dimethylbut-l-enyl. In some embodiments, the alkenyl is preferably
a branched alkenyl of 3 to 4 carbon atoms. The term "lower alkenyl" refers to an alkenyl
group having 1 to 3 carbon atoms.

WO 2006/116136 PCT/US2006/015172
5
[0019] The terms "effective amount" and "therapeutically effective amount," as used
herein, refer to the amount of a compound of formula I that, when administered to a patient,
is effective to at least partially treat a condition from which the patient is suffering. Such
conditions include, melatoninergic disorders including, but not limited to, depression and
sleep disorders.
[0020] The term "pharmaceutically acceptable salts" or "pharmaceutically acceptable
salt" refers to salts derived from treating a compound of formula I with an organic or
inorganic acid such as, for example, acetic, lactic, citric, cinnamic, tartaric, succinic, fumaric,
maleic, malonic, mandelic, malic, oxalic, propionic, hydrochloric, hydrobromic, phosphoric,
nitric, sulfuric, glycolic, pyruvic, methanesulfonic, ethanesulfonic, toluenesulfonic, salicylic,
benzoic, or similarly known acceptable acids. In certain embodiments, the present invention
relates to the hydrochloride salt of a compound of formula I.
[0021] The term "patient," as used herein, refers to a mammal. In certain embodiments,
the term "patient," as used herein, refers to a human.
[0022] The terms "administer," "administering," or "administration," as used herein, refer
to either directly administering a compound or composition to a patient, or administering a
prodrug derivative or analog of the compound to the patient, which will form an equivalent
amount of the active compound or substance within the patient's body.
[0023] The terms "treat" or "treating," as used herein, refers to partially or completely
alleviating, inhibiting, preventing, ameliorating and/or relieving the condition.
[0024] The terms "suffer" or "suffering," as used herein, refers to one or more conditions
that a patient has been diagnosed with, or is suspected to have.
2. Description of Exemplary Compounds:
[0025] In certain embodiments, the invention relates to a compound of formula I:

or pharmaceutically acceptable salts thereof, wherein:
m is 1 or 2;
n is 0 or 1;
y is 0, 1, 2, or 3;

WO 2006/116136 PCT/US2006/015172
6
each R1 is independently -CN, halogen, -R, or -OR;
each R is independently hydrogen, CM aliphatic, or fluoro-substituted CM aliphatic;
Ar is thienyl, furyl, pyridyl, or phenyl wherein Ar is optionally substituted with one or more
Rx groups;
each Rx is independently halogen, phenyl, -CN, -R, or -OR;
R is hydrogen or C1.4 aliphatic; and
X is 0, S, S(O), S02 or CH2.
[0026] As defined generally above, the n group of formula I is 0 or 1. In certain
embodiments, n is 1 thus forming a compound of formula la:

or a pharmaceutically acceptable salt thereof, wherein R1, R2, X, Ar, y, and m are as defined
above for compounds of formula I and in classes and subclasses as described above and
herein.
[0027] According to another embodiment, the n group of formula I is 0, thus forming a
compound of formula lb:

or a pharmaceutically acceptable salt thereof, wherein R , R , X, Ar, y, and m are as defined
above for compounds of formula I and in classes and subclasses as described above and
herein.
[0028] As defined generally above, y is 0-3 and each R1 group of formula I is
independently -CN, halogen, -R, or -OR. In certain embodiments, y is 0. In other
embodiments, y is other than 0 and at least one R1 group of formula I is halogen. In still
other embodiments, y is 1, and R1 is halogen, methyl, or ethyl.
[0029] According to one embodiment, y is 1, n is 1, and R is at the 6- or 7-position of the
bicyclic ring of formula I, thus forming a compound of formula IIa or IIb:

WO 2006/116136 PCT/US2006/015172
7

or a phannaceutically acceptable salt thereof, wherein each R , R , X, Ar, and m are as
defined above for compounds of formula I and in classes and subclasses as described above
and herein.
[0030] According to another embodiment, y is 1, n is 0, and R1 is at the 5- or 6-position
of the bicyclic ring of formula I, thus forming a compound of formula lie or lid:

or a phannaceutically acceptable salt thereof, wherein each R , R , X, Ar, and m are as
defined above for compounds of formula I and in classes and subclasses as described above
and herein.
[0031] As defined generally above, the Ar group of formula I is thienyl, furyl, pyridyl, or
phenyl, wherein Ar is optionally substituted with one or more subsituents independently
selected from halogen, phenyl, -CN, -R, or -OR. In certain embodiments, the Ar group of
formula I is unsubstituted phenyl. In other embodiments, the Ar group of formula I is phenyl
with at least one substituent in the ortho position. In other embodiments, the Ar group of
formula I is phenyl with at least one substituent in the ortho position selected from halogen,
lower alkyl, lower alkoxy, or trifluoromethyl. According to another aspect the present
invention provides a compound of formula I wherein Ar is phenyl disubstituted in the ortho
and meta positions with independently selected halogen, lower alkyl, or lower alkoxy. Yet
another aspect of the present invention provides a compound of formula I wherein Ar is
phenyl disubsituted in the ortho and para positions with independently selected halogen lower
alkyl, or lower alkoxy. In other embodiments, the present invention provides a compound of
formula I wherein Ar is phenyl disubsituted in the ortho positions with independently
selected halogen, lower alkyl, or lower alkoxy. Exemplary substituents on the phenyl moiety
of the Ar group of formula I include OMe, fluoro, chloro, methyl, and trifiuoromethyl.

WO 2006/116136 PCT/US2006/015172
8
[0032] In certain embodiments, the present invention provides a compound of formula
Hd wherein Ar is phenyl with one substituent in the ortho position selected from halogen,
lower alkyl, lower alkoxy, or trifluoromethyl.
[0033] According to one embodiment, Ar is phenyl substituted with Rx in the ortho-
position thus forming a compound of formula Ilia or Illb:

wherein each R1, R2, X, Rx, y and m are as defined above for compounds of formula I and in
classes and subclasses as described above and herein.
[0034] In certain embodiments, Ar is phenyl disubstituted with Rx in the ortho-positions
thus forming a compound of formula IVa or IVb:

wherein each R1, R2, X, Rx, y and m are as defined above for compounds of formula I and in
classes and subclasses as described above and herein.
[0035] According to another embodiment, the present invention provides a compound of
formula IVc or IVd:

wherein each R1, R2, X, Rx, y and m are as defined above for compounds of formula I and in
classes and subclasses as described above and herein.

WO 2006/116136 PCT/US2006/015172
9
[0036] In certain embodiments, the Ar group of formula I is selected from the following:

[0037] As defined generally above, the R2 of formula I is hydrogen or C14 aliphatic. In
certain embodiments, the R2 of formula I is hydrogen, methyl, ethyl, propyl, cyclopropyl or
cyclobutyl. In other embodiments, the R2 group of formula I is hydrogen, methyl or ethyl. In
yet other embodiments, R2 is methyl.
[0038] According to another embodiment, the present invention provides a compound of
formula I wherein X is O or CH2, m is 1 or 2, and n is 0 or 1. According to yet another
embodiment, X is CH2, m is 1, and n is 0, thus forming a compound of formula IV:

wherein each R1, R2, and Ar are as defined above for compounds of formula I and in classes
and subclasses as described above and herein.
[0039] Compounds of the present invention contain asymmetric carbon atoms and thus
give rise to stereoisomers, including enantiomers and diastereomers. Accordingly, it is
contemplated that the present invention relates to all of these stereoisomers, as well as to
mixtures of the stereoisomers. Throughout this application, the name of the product of this
invention, where the absolute configuration of an asymmetric center is not indicated, is

WO 2006/116136 PCT/US2006/015172
10
intended to embrace the individual stereoisomers as well as mixtures of stereoisomers. In
certain embodiments of the invention, compounds having an absolute (R) configuration are
preferred.
[0040] In certain embodiments, the present invention provides a compound of formula
Va,Vb,Vc,orVd:

wherein each R1, Rz, X, Ar, y and m are as defined above for compounds of formula I and in
classes and subclasses as described above and herein.
[0041] According to another embodiment, the present invention provides a compound of
formula VIa, VIb, VIc, or VId:


WO 2006/116136 PCT/US2006/015172
11
wherein each R1, R2, X, Rx, y and ro are as defined above for compounds of formula I and in
classes and subclasses as described above and herein.
[0042] According to another aspect of the present invention, a compound of formula
VIIa or VIIb is provided:

wherein each R1, R2, X, Rx, and m are as defined above for compounds of formula I and in
classes and subclasses as described above and herein.
[0043] Where an enantiomer is preferred, it may, in some embodiments be provided
substantially free of the corresponding enantiomer. Thus, an enantiomer substantially free of
the corresponding enantiomer refers to a compound which is isolated or separated via
separation techniques or prepared free of the corresponding enantiomer. "Substantially free,"
as used herein, means that the compound is made up of a significantly greater proportion of
one enantiomer. In certain embodiments the compound is made up of at least about 90% by
weight of a preferred enantiomer. In other embodiments of the invention, the compound is
made up of at least about 99% by weight of a preferred enantiomer. Preferred enantiomers
may be isolated from racemic mixtures by any method known to those skilled in the art,
including chiral high pressure liquid chromatography (HPLC) and the formation and
crystallization of chiral salts of intermediates of the compounds as described herein or
prepared by methods described herein. See, for example, Jacques, et al., Enantiomers,
Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen, S.H., et al.,
Tetrahedron 33:2725 (1977); Eliel, E.L. Stereochemistry of Carbon Compounds (McGraw-
Hill, NY, 1962); Wilen, S.H. Tables of Resolving Agents and Optical Resolutions p. 268
(E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972)..
[0044] It is further recognized that atropisomers of the present compounds may exit. The
present invention thus encompasses atropisomeric forms of compounds of formula I as
defined above, and in classes and subclasses described above and herein.
[004S] Exemplary compounds of formula I are set forth in Table 1, below.

WO 2006/116136 PCT/US2006/015172
12
Table 1: Exemplary Compounds of Formula I:


WO 2006/116136 PCT/US2006/015172
13

3. Genera! Methods of Providing the Present Compounds:
[0046] The dihydroberizofuran derivatives of the present invention are prepared as
illustrated in Scheme 1, below. Unless otherwise noted, the variables are as defined above.
Specifically, the appropriately substituted o-bromoanisole is converted to the corresponding
boronic acid via metallation with n-butyl lithium, treatment of the lithio derivative with
triisopropyl borate and hydrolysis of the resulting borate ester with aqueous hydrochloric
acid. The boronic acid thus obtained was then caused to undergo a Suzuki coupling reaction
by treatment with the appropriately substituted aryl bromide in the presence of a suitable
palladium catalyst such as tetrakis(triphenylphosphine)palladium(0) and a base such as
sodium carbonate. The ether is then cleaved via treatment with a demethylating agent such as
boron tribromide and the resulting phenol alkylated with allyl bromide in the presence of a
base such as sodium carbonate. The bi-aryl allyl ether is caused to undergo a Claisen
rearrangement via refluxing in a high boiling solvent such as decahydronaphthalene,
mesitylene or dimethylaniline and the rearranged olefin is then epoxidized with m-
chloroperoxybenzoic acid. Treatment with a base such as sodium carbonate in methanol
catalyzes the ring closure to the dihydrobenzofuran methanol. The resulting alcohol is
converted to a leaving group via treatment with p-toluenesulfonyl chloride in pyridine and the
tosylate displaced with sodium azide in a suitable solvent such as N,N-dimethylformamide.
Reduction of the azide by hydrogenation over a suitable catalyst such as sulfided platinum on
carbon and acylation of the resulting primary amine with a suitable acid chloride or anhydride
in the presence of a base such as diisopropylethylamine gives the dihydrobenzofuran title
compounds of the invention (I).

WO 2006/116136 PCT/US2006/015172
14
Scheme 1

[0047] Alternatively, as shown in Scheme 2 below, the appropriately substituted o-
bromophenol is alkylated with allyl bromide in the presence of a suitable base such as sodium
carbonate and the resulting ether caused to undergo the Claisen rearrangement via reflux in a
high boiling solvent such as decahydronaphthalene, mesitylene or N,N-dimethylaniline. The
rearranged olefin is then epoxidized by treatment with m-chloroperoxbenzoic acid and the
resulting epoxide cyclized to the dihydrobenzofuran methanol by treatment with a base such
as sodium carbonate in methanol. The primary alcohol is then converted to the p-
toluenesulfonylate by treatment with p-toluenesulfonyl chloride in pyridine. The resulting
bromo-substituted dihydrobenzofuran methyltosylate is then made to undergo Suzuki
coupling reactions by treatment with the appropriately substituted aryl boronic acids in the
presence of a suitable palladium catalyst such as tetrakis(triphenylphosphine)palladium(0)
and a base such as sodium carbonate. As before, replacement of the tosylate with azide,
followed by azide reduction and acylation with the appropriate acyl chloride or anhydride
gives the title compounds (I) of the invention.

WO 2006/116136 PCT/US2006/015172
15
Scheme 2

[0048] The compounds of the invention may also be prepared in a stereospecific manner
via Scheme 3 below. The appropriately substituted o-bromo anisole is metallated by
treatment with n-butyl lithium and converted to the cuprate via reaction with copper (I)
bromide dimethyl sulfide complex. The resulting cuprate is caused to react with the epoxide
moiety of enantiopure (R)- or (S)-glycidyl benzyl ether in the presence of a catalyst such as
boron trifluoride etherate. The resulting protected glycol is demethylated and converted to the
bromo-acetate by treatment with 30% hydrogen bromide in acetic acid. Following hydrolysis
of the acetyl group with hydrogen chloride in methanol, the dihydrobenzofuran ring is formed
via a Mitsonobu reaction by treatment with triphenylphosphine and
diethylazidodicarboxylate. The resulting dihydrobenzofuran methylbromide is then
brominated by treatment with bromine in acetic acid. Following the same sequences shown
in Scheme 2, the title compounds (I) of the invention can be made.

WO 2006/116136 PCT/US2006/015172
16
Scheme 3

[0049] According to an alternate method, as depicted in Scheme 4 below, the
appropriately substituted o-methoxyphenylboronic acid is caused to undergo the Suzuki
coupling by treatment with the appropriately substituted aryl bromide in the presence of a
suitable palladium catalyst such as tetrakis(triphenylphosphine)palladium(0) and a base such
as sodium hydroxide. The resulting bi-aryl methyl ether is brominated with N-
bromosuccinamide in acetic acid. The bromo compound is then converted to the Grignard
reagent via exchange with isopropyl magnesium chloride and then to the cuprate by treatment
with copper(I)iodide. The resulting cuprate is caused to react with the epoxide moiety of
enantiopure (R)- or (S)-glycidyl p-tosylate to give the glycol mono-p-tosylate. Reaction with
potassium phthalimide is followed by conversion of the secondary alcohol to the mesylate by
reaction with methanesulfonyl chloride and triethylamine. Demethylation under the
influence of boron tribromide and ring closure by treatment with a suitable base such as
sodium carbonate gives the enantiopure dihydrobenzofuran. Removal of the phthalimido
protecting group with hydrazine and acylation of the resulting amine with the appropriate
acyl chlorides or anhydrides gives the compounds of the invention.

WO 2006/116136 PCT/US2006/015172
17
Scheme 4

[0050] In addition to the synthetic methods described above, the stereoisomers of the
present invention are also prepared by the stereoselective processes described in United
States provisional patent application serial number 60/621,023, filed October 21, 2004, and
United States provisional patent application serial number 60/621,024, filed October 21,
2004, the entirety of both of which is hereby incorporated herein by reference.
[0051] Although certain exemplary embodiments are depicted and described above and
herein, it will be appreciated that compounds of the invention can be prepared according to
the methods described generally above using appropriate starting materials by methods
generally available to one of ordinary skill in the art. Additional embodiments are
exemplified in more detail herein.
4. Uses, Formulation and Administration
[0052] Compounds of the present invention have affinity for and agonist or partial
agonist activity for melatonin receptors and are thus of interest for the treatment of
melatoninergic related disorders. As used herein, the term "melatoninergic disorder" means
any disease or other deleterious condition in which a deficiency in melatonin is known to
play a role. The term "melatoninergic disorder" also means those diseases or conditions that
are alleviated by treatment with a melatoninergic agonist or partial agonist. In certain
embodiments, such melatoninergic disorders include circadian rhythm disorders, depression,

WO 2006/116136 PCT/US2006/015172
18
sleep disorders, Parkinson's disease, Alzheimer's disease, obesity, and diabetes. A more
complete description of the aforementioned mental disorders can be found in the Diagnostic
and Statistical Manual of Mental Disorders, 4th edition, Washington, DC, American
Psychiatric Association (1994), incorporated herein by reference in its entirety.
10053] In certain embodiments, the compounds of the present invention are useful for
treating stress, sleep disorders, anxiety, seasonal affective disorder, cardiovascular
pathologies, pathologies of the digestive system, insomnia and fatigue due to jetlag,
schizophrenia, panic attacks, melancholia, appetite disorders, obesity, insomnia, psychotic
disorders, epilepsy, diabetes, Parkinson's disease, senile dementia, various disorders
associated with normal or pathological ageing, migraine, memory loss, Alzheimer's disease,
or in cerebral circulation disorders. In another embodiment, compounds of the present
invention are useful for the treatment of sexual dysfunctions, and have ovulation-inhibiting
and immunomodulating properties.
[0054] In other embodiments, the compounds of the present invention are useful for
treating seasonal affective disorder, sleep disorders, cardiovascular pathologies, insomnia and
fatigue due to jetlag, appetite disorders or obesity.
[0055] In still other embodiments, the compounds of the present invention are useful for
treating depression or sleep disorders.
[0056] The compounds of formula I are also of interest for the treatment of epilepsy;
migraines; sexual dysfunction; sleep disorders; substance abuse, including addiction to
alcohol and various drugs, including cocaine and nicotine; gastrointestinal disorders, such as
malfunction of gastrointestinal motility; and obesity, with its consequent comorbidities
including Type II diabetes, cardiovascular disease, hypertension, hyperlipidemia, stroke,
osteoarthritis, sleep apnea, gall bladder disease, gout, some cancers, some infertility, and
early mortality.
[0057] The compounds of formula I can also be used to treat central nervous system
deficiencies associated, for example, with trauma, stroke, and spinal cord injuries. The
compounds of formula I can therefore be used to improve or inhibit further degradation of
central nervous system activity during or following the malady or trauma in question.
Included in these improvements are maintenance or improvement in motor and motility
skills, control, coordination and strength.
[0058] In certain embodiments, the present invention therefore provides methods of
treating, each of the conditions listed above in a patient, preferably in a human, the methods

WO 2006/116136

19

PCT/US2006/015172

including administering a therapeutically effective amount of at least one compound of
formula I or a pharmaceutically acceptable salt thereof to a patient suffering from such a
condition.
5. Pharmaceutically acceptable compositions
[0059] In other embodiments, the invention relates to compositions comprising at least
one compound of formula I, or a pharmaceutically acceptable salt thereof, and one or more
pharmaceutically acceptable carriers, excipients, or diluents. Such compositions include
pharmaceutical compositions for treating or controlling disease states or conditions of the
central nervous system. In certain embodiments, the compositions comprise mixtures of one
or more compounds of formula I.
[0060] In certain embodiments, the invention relates to compositions comprising at least
one compound of formula I, or a pharmaceutically acceptable salt thereof, and one or more
pharmaceutically acceptable carriers, excipients, or diluents. Such compositions are prepared
in accordance with acceptable pharmaceutical procedures, such as, for example, those
described in Remingtons Pharmaceutical Sciences, 17th edition, ed. Alfonoso R. Gennaro,
Mack Publishing Company, Easton, PA (1985), which is incorporated herein by reference in
its entirety. Pharmaceutically acceptable carriers are those carriers that are compatible with
the other ingredients in the formulation and are biologically acceptable.
[0061] The compounds of formula I can be administered orally or parenterally, neat, or in
combination with conventional pharmaceutical carriers. Applicable solid carriers can include
one or more substances that can also act as flavoring agents, lubricants, solubilizers,
suspending agents, fillers, glidants, compression aids, binders, tablet-disintegrating agents, or
encapsulating materials. In powders, the earner is a finely divided solid that is in admixture
with the finely divided active ingredient. In tablets, the active ingredient is mixed with a
carrier having the necessary compression properties in suitable proportions and compacted in
the shape and size desired. The powders and tablets preferably contain up to 99% of the
active ingredient. Suitable solid carriers include, for example, calcium phosphate,
magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose,
sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange
resins.
[0062] Liquid carriers can be used in preparing solutions, suspensions, emulsions, syrups
and elixirs. The active ingredient can be dissolved or suspended in a pharmaceutically
acceptable liquid carrier such as water, an organic solvent, a mixture of both, or a

WO 2006/116136

PCT/US2006/015172

20
pharmaceutically acceptable oil or fat. The liquid carrier can contain other suitable
pharmaceutical additives such as, for example, solubilizers, emulsifiers, buffers,
preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors,
viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid carriers for
oral and parenteral administration include water (particularly containing additives as above,
e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols
(including monohydric alcohols and polyhydric alcohols e.g. glycols) and their derivatives,
and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration, the
carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid
carriers are used in sterile liquid form compositions for parenteral administration. The liquid
carrier for pressurized compositions can be halogenated hydrocarbon or other
pharmaceutically acceptable propellant.
[0063] Liquid pharmaceutical compositions that are sterile solutions or suspensions can
be administered by, for example, intramuscular, intraperitoneal or subcutaneous injection.
Sterile solutions can also be administered intravenously. Compositions for oral
administration can be in either liquid or solid form.
[0064] The compounds of formula I can be administered rectally or vaginally in the form
of a conventional suppository. For administration by intranasal or intrabronchial inhalation or
insufflation, the compounds of formula I can be formulated into an aqueous or partially
aqueous solution, which can then be utilized in the form of an aerosol. The compounds of
Formula 1 can also be administered transdermally through the use of a transdermal patch
containing the active compound and a carrier that is inert to the active compound, is non-
toxic to the skin, and allows delivery of the agent for systemic absorption into the blood
stream via the skin. The carrier can take any number of forms such as creams and ointments,
pastes, gels, and occlusive devices. The creams and ointments can be viscous liquid or
semisolid emulsions of either the oil-in-water or water-in-oil type. Pastes comprised of
absorptive powders dispersed in petroleum or hydrophilic petroleum containing the active
ingredient can also be suitable. A variety of occlusive devices can be used to release the
active ingredient into the blood stream such as a semipermeable membrane covering a
reservoir containing the active ingredient with or without a carrier, or a matrix containing the
active ingredient. Other occlusive devices are known in the literature.
[0065] Preferably the pharmaceutical composition is in unit dosage form, e.g. as tablets,
capsules, powders, solutions, suspensions, emulsions, granules, or suppositories. In such

WO 2006/116136 PCT/US2006/015172
21
form, the composition is sub-divided in unit dose containing appropriate quantities of the
active ingredient; the unit dosage forms can be packaged compositions, for example,
packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids. The unit
dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate
number of any such compositions in package form.
[0066] The amount of compound of formula I provided to a patient will vary depending
upon what is being administered, the purpose of the administration, such as prophylaxis or
therapy, the state of the patient, the manner of administration, and the like. In therapeutic
applications, compounds of formula I are provided to a patient suffering from a condition in
an amount sufficient to treat or at least partially treat the symptoms of the condition and its
complications. An amount adequate to accomplish this is a "therapeutically effective
amount" as described previously herein. The dosage to be used in the treatment of a specific
case must be subjectively determined by the attending physician. The variables involved
include the specific condition and the size, age, and response pattern of the patient. The
treatment of substance abuse follows the same method of subjective drug administration
under the guidance of the attending physician. Generally, a starting dose is about 5 mg per
day with gradual increase in the daily dose to about 150 mg per day, to provide the desired
dosage level in the patient.
[0067] In certain embodiments, the present invention is directed to prodrugs of
compounds of formula I. The term "prodrug," as used herein, means a compound that is
convertible in vivo by metabolic means (e.g. by hydrolysis) to a compound of formula I.
Various forms of prodrugs are known in the art such as those discussed in, for example,
Bundgaard, (ed,), Design of Prodrugs, Elsevier (1985); Widder, et al. (ed.), Methods in
Enzymology, vol. 4, Academic Press (1985); Krogsgaard-Larsen, et al., (ed). "Design and
Application of Prodrugs, Textbook of Drug Design and Development, Chapter 5, 113-191
(1991), Bundgaard, et al., Journal of Drug Delivery Reviews, 8:1-38(1992), Bundgaard, J. of
Pharmaceutical Sciences, 77:285 et seq. (1988); and Higuchi and Stella (eds.) Prodrugs as
Novel Drug Delivery Systems, American Chemical Society (1975), each of which is hereby
incorporated by reference in its entirety.

WO 2006/116136 PCT/US2006/015172
22
EXAMPLES
[0068] As depicted in the Examples below, in certain exemplary embodiments,
compounds are prepared according to the following general procedures. It will be
appreciated that although the general methods depict the synthesis of certain compounds of
the present invention, the following general methods, in addition to the Schemes set forth
above and other methods known to one of ordinary skill in the art, can be applied to all
compounds and subclasses and species of each of these compounds, as described herein.
[0069] The following examples illustrate the preparation of representative compounds of
the present invention. Each intermediate as described herein was prepared according to the
methods used to prepare the same, as described in detail in United States patent application
serial number 10/970,714, filed October 21, 2004, the entirety of which is hereby
incorporated herein by reference.
Example 1
(R)-N-[7-(2,6-Dichloro-phenyl)-5-fluoro-2,3-dihydro-benzofuran-2-yimethylj-
acetamide:
(R)-[7-(2,6-Dichloro-phenyl)-5-fluoro-2,3-dihydro-benzofuran-2-yl]-methylamine
hydrochloride (0.050 g, 0.14 mmol) was suspended in 5.0 mL of methylene chloride and
diisopropylethylamine (0.072 g, 0.56 mmol) and acetic anhydride (0.029 g, 0.28 mmol)
added. The mixture was stirred at room temperature for 30 rain, diluted to 100 mL with
methylene chloride, washed with 50 mL portions of 2 N HC1 (aqueous), saturated aqueous
sodium bicarbonate and saturated brine. The solution was dried over sodium sulfate, filtered
and concentrated in vacuum to give 0.043 g of the title compound as a white crystalline solid.
'H-NMR (CDC13): multiplet 7.4 S (1 H); multiplet 7.33 5 (2 H); doublet 6.95 5 (1 H);
doublet 6.72 5 (1 H); broad singlet 5.8 5 (1 H); multiplet 4.9 5 (1 H); doublet of doublets 3.6
5 (1 H); doublet of doublets 3.47 5 (1 H); doublet of doublets 3.38 5 (1 H); doublet of
doublets 3.0 5 (1 H); singlet 1.9 5 (3 H).
Example 2
N-[7-(2,6-Dichloro-phenyl)-2,3-dihydro-benzofuran-2-yImethylJ-acetainide: [7-(2,6-
Dichloro-phenyl)-2,3-dihydro-benzofuran-2-yl]-methylamine hydrochloride (0.050 g, 0.17

WO 2006/116136 PCT/US2006/015172
23
mmol) was suspended in 5.0 mL of methylene chloride and diisopropylethylamine (0.072 g,
0.56 mmol) and acetic anhydride (0.029 g, 0.28 mmol) added. The mixture was stirred at
room temperature for 30 min, diluted to 100 mL with methylene chloride, washed with 50
mL portions of 2 N HC1 (aqueous), saturated aqueous sodium bicarbonate and saturated
brine. The solution was dried over sodium sulfate, filtered and concentrated in vacuum to
give 0.038 g of the title compound as a white crystalline solid.
Example 3
N-[7-(2-ChIoro-phenyI)-2,3-dihydro-benzofuran-2-ylmethyI]-acetamide: [7-(2-Chloro-
phenyl)-2,3-dihydro-benzofuran-2-y]]-methylamine hydrochloride (0.050 g, 0.17 mmol) was
suspended in 5.0 mL of methylene chloride and diisopropylethylamine (0.072 g, 0.56 mmol)
and acetic anhydride (0.029 g, 0.28 mmol) added. The mixture was stirred at room
temperature for 30 min, diluted to 100 mL with methylene chloride, washed with 50 mL
portions of 2 N HC1 (aqueous), saturated aqueous sodium bicarbonate and saturated brine.
The solution was dried over sodium sulfate, filtered and concentrated in vacuum to give
0.047 g of the title compound as an oil which slowly hardened to a white solid in vacuum.
lH-NMR (CDC13): doublet of doublets 7.48 5 (1 H); multiplet 7.33 5 (2 H); doublet 7.2 5 (1
H); doublet 7.06 8 (1 H); triplet 6.93 8 (1 H); broad singlet 5.95 6 (1 H); multiplet 4.9 5 (1
H); doublet of doublets 3.7 8 (1 H); doublet of doublets 3.45 5 (1 H); doublet of doublets 3.35
5 (1 H), doublet of doublets 3.0 8 (1 H), singlet 1.95 8 (3 H).
Examples 4-16
[0070] The following compounds are prepared from the appropriate amine
hydrochlorides in a manner substantially similar to the procedures described in Examples 1-3
above:
N-[7-(2-Trifluoromethyl-phenyl)-2,3-dihydro-benzofuran-2-ylmethyl]-acetamide;
N-[7-(2,4-DichIoro-phenyl)-2,3-dihydro-benzofuran-2-ylmethyl]-acetamide;
(R)-N-[7-(2,5-Dichloro-phenyl)-2,3-dihydro-benzofuran-2-yImethyI]-acetamide;
N-[7-(2-Chloro-phenyl)-5-fluoro-2,3-dihydro-benzofuran-2-ylmethyl]~acetamide;
N-[5-Chloro-7-(2-chloro-phenyl)-2,3-dihydro-benzofuran-2-y]methyl]-acetamide;
N-[7-(2-Chloro-phenyl)-5-methyl-2,3-dihydro-benzofuran-2-ylmethyl]-acetamide;

WO 2006/116136

24

PCT/US2006/015172

N-[7-(2-Chloro-phenyl)-5-ethyl-2,3-dihydro-benzofuran-2-ylmethyl]-acetamide;
(R)-N-[7-2-Chloro-6-methyl-phenyl)-5-methyl-2,3-dihydro-benzofuran-2-ylmethyl]-
acetamide;
(R)-N-(5-Fluoro-7-o-tolyl-2,3-dihydro-benzofuran-2-ylmethyl)-acetamide;
N-[7-(2,6-Difluoro-phenyl)-5 -fluoro-2,3 -dihydro-benzofuran-2-ylrnethyl] -acetamide;
N-[7-(2,6-Dimethyl-phenyl)-5-fluoro-2,3-dihydro-benzofuran-2-ylmethyl]-acetamide;
N47-(2-Chloro-phenyI)-6-fluoro-2,3-dihydro-benzoftiran-2-ylmethy]]-acetarnide; and
N-(6-Fluoro-7-o-tolyl-2,3-dihydro-benzofiaran-2-ylmethyl)-acetamide.
Biological Assays
[0071] The ability of the compounds of this invention to act as melatonin agonists and
partial agonists is established using several standard pharmacological test procedures; the
procedures are provided below.
[0072] Using a method substantially similar to that described by Audinot, V., et al, "New
selective ligands of human cloned melatonin MT1 and MT2 receptors" Nauyn-
Schmiedeberg's Arch Pharmacol 2003 367:553-561, human cloned MT1 and MT2 receptors
are stably expressed in HEK-293 or CHO cells, the cells grown at confluence , harvested in
phosphate buffer containing 2 mM EDTA and centrifuged at 1000g and 4 °C for five
minutes. The resulting pellet is suspended in 5 mM Tris/HCl, pH 7.4, containing 2 mM
EDTA and homogenized using a Kinematica polytron. The homogenate is then centrifuged
(20,000 g, 30 min, 4 deg C) and the resulting pellet suspended in 75 mM Tris/HCl, pH 7.4,
containing 2 mM EDTA and 12.5 mM MgCl2. Aliquots of membrane preparations are stored
in binding buffer (Tris/HCl 50 mM, pH 7.4, 5 mM MgCl2) at -80 deg C until use.
[0073] Membranes are incubated for 2 hours at 37 °C in binding buffer in a final volume
of 250 uL containing 2-[]25I]-melatonin 20 pM for competition in CHO cells and 25 or 200
pM, respectively, for MTI and MT2 cells expressed in HEK cells. The results are expressed
as KJ; non-specific binding is defined with 10 uM melatonin. Reaction is stopped by rapid
filtration through GF/B unifilters, followed by three successive washes with ice cold buffer.
Data are analyzed by using the program PRISM (GraphPad Software, Inc., San Diego, CA).
For saturation assay, the density of binding sites Bmax and the dissociation constant of the

WO 2006/116136

25

PCT/US2006/015172

radioligand (KD) values are calculated according to the method of Scatchard. For
competition experiments, inhibition constants (Kj) are calculated according to the Cheng-
Prussof equation: Ki = ICso/fl + (L/KD)]5 where IC50 is the Inhibitory Concentration 50% and
L is the concentration of radioligand.
[0074] The entire disclosure of each patent, patent application, and publication cited or
described in this document is hereby incorporated by reference.
[0075] While we have presented a number of embodiments of this invention, it is
apparent that our basic construction can be altered to provide other embodiments which
utilize the compounds and methods of this invention. Therefore, it will be appreciated that
the scope of this invention is to be defined by the appended claims rather than by the specific
embodiments which have been represented by way of example.

WO 2006/116136 PCT/US2006/015172
26
CLAIMS
We claim:
1. A compound of formula I :

or pharmaceutically acceptable salts thereof, wherein:
m is 1 or 2;
n is 0 or 1;
y is 0, 1, 2, or 3;
each R1 is independently -CN, halogen, -R, or -OR;
each R is independently hydrogen, C1-4 aliphatic, or fluoro-substituted C1-4 aliphatic;
Ar is thienyl, furyl, pyridyl, or phenyl wherein Ar is optionally substituted with one or more
Rx groups;
each Rx is independently halogen, phenyl, -CN, -R, or -OR;
R is hydrogen or C1-4 aliphatic; and
X is -0-, -S-, -S(O)-, -S02- or -CH2-.
2. The compound according to claim 1, wherein said compound is of formula la:

or a pharmaceutically acceptable salt thereof.
3. The compound according to claim 2, wherein each R1 is independently -R, -
CN, halogen, -OR, trifluoromethyl, or -OCF3.

WO 2006/116136 PCT/US2006/015172
27
4. The compound according to claim 3, wherein said compound has the formula
IIa or IIb:

or a pharmaceutically acceptable salt thereof.
5. The compound according to claim 2 or 3, wherein said compound is of
formula Ilia, TVa, or IVc:

or a pharmaceutically acceptable salt thereof.
6, The compound according to any one of claims 1 to 5, wherein each Rx is
independently selected from -R, halogen, -OR, or trifluoromethyl.
7. The compound according to any one of claims 1 to 4, wherein:
X is -O- or -CH2-;
each R1 is independently -R, -CN, halogen, -OR, or trifluoromethyl;
R2 is hydrogen, methyl, ethyl, propyl, cyclopropyl or cyclobutyl;
Ar is pyridyl, thienyl, furanyl, or phenyl, wherein Ar is optionally substituted with one or
more Rx groups; and

WO 2006/116136 PCT/US2006/015172
28
each Rx is independently selected from -R, -CN, halogen, -OR, or trifluoromethyl.
8. The compound according to claim 1, wherein said compound is of formula lb:

or a pharmaceutically acceptable salt thereof.
9. The compound according to any one of claims 1 to 8, wherein each R1 is
independently -R, halogen, -OR, or trifluoromethyl.
10. The compound according to claim 8 or 9, wherein said compound is of
formula IIc or IId:

or a pharmaceutically acceptable salt thereoi.
11. The compound according to any one of claims 1 to 4, 7 or 8, wherein Ar is
pyridyl, thienyl, or furanyl.
12. The compound according to claim 8, wherein said compound is of formula
IIIb, IVb, oi IVd:


WO 2006/116136 PCT/US2006/015172
29

or a phaxmaceutically acceptable salt thereof.
13. The compound according to claim 12, wherein each Rx is independently
selected from -R, halogen, -OR, trifluoromethyl, -OCF3.
14. The compound according to claim 12, wherein:
X is-0-or-CH2-;
each R1 is independently -R, -CN, halogen, or -OR;
R2 is hydrogen, methyl, ethyl, propyl, cyclopropyl or cyclobutyl;
Ar is pyridyl, thienyl, furanyl, or phenyl, wherein Ar is optionally substituted with one or
more Rx groups; and
each Rx is independently selected from -R, -CN, halogen, or -OR.
15. The compound according to claim 1, wherein said compound is selected from-.

or a pharmaceutically acceptable salt thereof.
16. The compound according to claim 1, wherein said compound is selected from:


WO 2006/116136 PCT/US2006/015172
30
or a pharmaceutically acceptable salt thereof.
17. The compound according to claim 1, wherein said compound is selected from:

or a pharmaceutically acceptable salt thereof.
18. The compound according to any one of claims 1 to 10 or 12 to 17, wherein Ar is
selected from:


WO 2006/116136 PCT/US2006/015172
31

20. A composition comprising a compound according to any one of claims 1 to
19, and one or more pharmaceutical^ acceptable carriers.
21. A method for treating a patient suffering from a melatoninergic disorder
comprising administering to the patient a therapeutically effective amount of a compound
according to any one of claims. 1 to 19 or a composition according to claim 20.

WO 2006/116136 PCT/US2006/015172
32
22. The method according claim 21 wherein said melatoninergic disorder is
selected from depression, stress, a sleep disorder, anxiety, a seasonal affective disorder, a
cardiovascular pathology, a pathology of the digestive system, insomnia or fatigue due to
jetlag, schizophrenia, panic attacks, melancholia, an appetite disorder, obesity, insomnia, a
psychotic disorder, epilepsy, diabetes, Parkinson's disease, senile dementia, a disorder
associated with normal or pathological ageing, migraine, memory loss, Alzheimer's disease,
or a cerebral circulation disorder.
23. The method according to claim 22, wherein said melatoninergic disorder is
selected from a seasonal affective disorder, a sleep disorder, a cardiovascular pathology,
insomnia or fatigue due to jetlag, an appetite disorder or obesity.
24. The method according to claim 22, wherein said melatoninergic disorder is
selected from depression.
25. The method according to claim 22, wherein said melatoninergic disorder is a
sleep disorder.
26. The use of a compound according to any one of claims 1 to 19 in the
manufacture of a medicament for the treatment of a melatoninergic disorder selected from
depression, stress, a sleep disorder, anxiety, a seasonal affective disorder, a cardiovascular
pathology, a pathology of the digestive system, insomnia or fatigue due to jetlag,
schizophrenia, panic attacks, melancholia, an appetite disorder, obesity, insomnia, a psychotic
disorder, epilepsy, diabetes, Parkinson's disease, senile dementia, a disorder associated with
normal or pathological ageing, migraine, memory loss, Alzheimer's disease, or a cerebral
circulation disorder.

Compounds of formula (I) are provided: formula (I), wherein each of R1, R2, y, m, n, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of melatoninergic receptors. The compounds, and compositions containing the compounds, can be used to treat melatoninergic disorders.